Although the quantification of CSF biomarkers, such as Aβ1–42, total tau (T-tau), and phosphorylated tau (p-tau) proteins, has been incorporated into standard diagnostic guidelines for degenerative diseases such as AD, potential biomarkers for the diagnosis of hydrocephalus and responsiveness to receiving a shunt must also be explored. Here, MAPT is linked to neurodegenerative disease.